InMed Pharmaceuticals Inc. (INM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, InMed Pharmaceuticals reported revenue of $0, down 100.0% from $4.9M the year before. Net income was -$12.6M, or -$3.12 per diluted share. Operating activities generated -$8.6M of cash. At fiscal year end, InMed Pharmaceuticals held $3.0M in total assets against $2.0M in total liabilities.
Open the full interactive InMed Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
InMed Pharmaceuticals Key Stats
| Share Price | $1.33 |
|---|---|
| Market Cap | $5.5M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $0.62 – $2.20 |
| Shares Outstanding | 4.2 million (basic, 2026 Q4) |
InMed Pharmaceuticals Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.1M | $4.1M | $4.6M | $4.9M | $0 |
| Cost of Goods Sold | — | $545,889 | — | — | — | — |
| Gross Profit | — | $543,546 | $1.4M | $1.1M | $1.7M | — |
| Operating Income | — | -$18.6M | -$7.9M | -$8.2M | -$7.9M | — |
| Pre-Tax Income | -$10.2M | -$18.6M | -$7.9M | -$7.7M | -$8.2M | -$11.4M |
| Income Tax | — | — | $13,100 | $7,100 | — | $1.2M |
| Net Income | -$10.2M | -$18.6M | -$7.9M | -$7.7M | -$8.2M | -$12.6M |
| Diluted EPS | -$760.00 | -$663.40 | -$65.00 | -$20.20 | -$8.36 | -$3.12 |
InMed Pharmaceuticals Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $1.1M | $820,188 | $0 | — |
| Net Income | -$1.7M | -$2.0M | -$3.0M | -$5.8M |
| Diluted EPS | -$0.44 | -$0.51 | -$0.73 | -$1.40 |
InMed Pharmaceuticals Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.4M | $6.2M | $8.9M | $6.6M | $11.1M | — |
| Current Assets | $8.4M | $9.6M | $11.3M | $8.7M | $12.9M | $2.7M |
| Total Assets | $9.8M | $12.8M | $14.1M | $11.8M | $15.6M | $3.0M |
| Current Liabilities | $2.2M | $3.3M | $2.0M | $2.0M | $1.8M | $2.0M |
| Total Liabilities | $2.4M | $3.7M | $2.0M | $2.6M | $2.1M | $2.0M |
| Shareholders' Equity | $7.4M | $9.1M | $12.1M | $9.2M | $13.4M | $1.1M |
InMed Pharmaceuticals Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$9.8M | -$15.6M | -$7.3M | -$7.0M | -$7.8M | -$8.6M |
| Cash From Investing | -$1,725 | -$672,999 | -$661,804 | -$9,293 | — | — |
| Cash From Financing | $10.9M | $15.1M | $10.7M | $4.7M | $12.3M | $94,496 |
| Free Cash Flow | -$9.8M | -$15.6M | -$7.4M | -$7.0M | -$7.8M | — |
Figures from InMed Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full InMed Pharmaceuticals financials page for every line item.
InMed Pharmaceuticals Company Profile
| Ticker | INM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Vancouver |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001728328 |
Frequently Asked Questions
What was InMed Pharmaceuticals' revenue in fiscal 2026?
InMed Pharmaceuticals (INM) reported revenue of $0 for fiscal 2026.
What is InMed Pharmaceuticals' annual revenue history?
InMed Pharmaceuticals' annual revenue by fiscal year: 2021: $0; 2022: $1.1M; 2023: $4.1M; 2024: $4.6M; 2025: $4.9M; 2026: $0.
What was InMed Pharmaceuticals' net income in fiscal 2026?
InMed Pharmaceuticals reported net income of -$12.6M for fiscal 2026.
What was InMed Pharmaceuticals' earnings per share (EPS) in fiscal 2026?
InMed Pharmaceuticals' diluted EPS was -$3.12 for fiscal 2026 (adjusted for any later stock splits).
How many shares of InMed Pharmaceuticals are outstanding?
InMed Pharmaceuticals reported a weighted average of 4.2 million basic shares outstanding in 2026 Q4.
What is InMed Pharmaceuticals' market cap?
Based on its latest closing price, InMed Pharmaceuticals (INM) has a market capitalization of about $5.5M.
When does InMed Pharmaceuticals' fiscal year end?
InMed Pharmaceuticals' fiscal year end, as registered with the SEC, is June 30.
Where is InMed Pharmaceuticals headquartered?
InMed Pharmaceuticals lists its business address in Vancouver in its SEC filings.